Johannes Kramer
Overview
Explore the profile of Johannes Kramer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kramer J, Koller G, Pogarell O
Herz
. 2024 Sep;
49(6):428-433.
PMID: 39331072
The partial legalization of cannabis in Germany in 2024 will affect both medical and recreational use of cannabis. Tetrahydrocannabinol (THC), the main psychoactive component of the cannabis plant, influences heart...
2.
Kramer J, Koller G, Pogarell O
MMW Fortschr Med
. 2024 Aug;
166(14):56-62.
PMID: 39210134
No abstract available.
3.
Schnabel-Besson E, Garbade S, Gleich F, Grunert S, Kramer J, Thimm E, et al.
J Inherit Metab Dis
. 2024 Aug;
48(1):e12784.
PMID: 39189622
Newborn screening (NBS) is one of the most effective measures of secondary prevention. While the benefit of NBS on the clinical long-term outcomes of children with inherited metabolic diseases (IMD)...
4.
Pelzer L, Dietze K, Martinez-Lahuerta V, Krinner L, Kramer J, Dawel F, et al.
Phys Rev Lett
. 2024 Aug;
133(3):033203.
PMID: 39094148
We present the experimental realization of a continuous dynamical decoupling scheme which suppresses leading frequency shifts in a multi-ion frequency reference based on ^{40}Ca^{+}. By near-resonant magnetic coupling of the...
5.
Mengler K, Garbade S, Gleich F, Thimm E, May P, Lindner M, et al.
Pediatrics
. 2024 Jul;
154(2.
PMID: 38957900
Objective: Maple syrup urine disease (MSUD), a life-threatening metabolic disorder, is included in newborn screening (NBS) programs worldwide. The study aims to evaluate the impact of NBS on the long-term...
6.
Danz K, Fleddermann J, Koch M, Fecioru E, Maahs L, Kinsinger N, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794233
The treatment of Parkinson's disease has been moving into the focus of pharmaceutical development. Yet, the necessity for reliable model systems in the development phase has made research challenging and...
7.
Reischl-Hajiabadi A, Schnabel E, Gleich F, Mengler K, Lindner M, Burgard P, et al.
J Inherit Metab Dis
. 2024 Apr;
47(4):674-689.
PMID: 38563533
The current German newborn screening (NBS) panel includes 13 inherited metabolic diseases (IMDs). In addition, a NBS pilot study in Southwest Germany identifies individuals with propionic acidemia (PA), methylmalonic acidemia...
8.
Dawel F, Wilzewski A, Herbers S, Pelzer L, Kramer J, Hild M, et al.
Opt Express
. 2024 Mar;
32(5):7276-7288.
PMID: 38439412
Optical resonators are used for the realisation of ultra-stable frequency lasers. The use of high reflectivity multi-band coatings allows the frequency locking of several lasers of different wavelengths to a...
9.
Floroiu A, Loretz B, Kramer J, Lehr C
Eur J Pharm Biopharm
. 2024 Feb;
197:114206.
PMID: 38316234
An inhalation-based Biopharmaceutics Classification System for pulmonary drugs (iBCS) holds the perspective to allow for scientifically sound prediction of differences in the in vivo performance of orally inhaled drug products...
10.
Brunet T, Zott B, Lieftuchter V, Lenz D, Schmidt A, Peters P, et al.
Genet Med
. 2023 Nov;
26(2):101013.
PMID: 37924258
Purpose: RNF213, encoding a giant E3 ubiquitin ligase, has been recognized for its role as a key susceptibility gene for moyamoya disease. Case reports have also implicated specific variants in...